Financial Performance - The company's operating revenue for Q3 2023 reached ¥3,960,683,771.21, representing a 16.72% increase compared to ¥3,393,267,938.15 in the same period last year[4] - Net profit attributable to shareholders for Q3 2023 was ¥404,165,999.83, a 55.81% increase from ¥259,391,422.53 year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was ¥398,816,142.03, up 56.54% from ¥254,774,836.52 in the previous year[4] - Basic earnings per share for Q3 2023 increased to ¥0.295, reflecting a growth of 56.08% compared to ¥0.189 in the same quarter last year[5] - Total operating revenue for the first three quarters of 2023 reached ¥13,721,380,016.26, a 25.5% increase from ¥10,900,279,219.19 in the same period of 2022[16] - Net profit for the first three quarters of 2023 was ¥2,173,313,513.02, representing a 48.9% increase compared to ¥1,459,474,526.09 in 2022[18] - Earnings per share for the first three quarters of 2023 was ¥1.014, compared to ¥0.731 in the same period of 2022[19] - The company reported a comprehensive income total of ¥2,255,099,924.18 for the first three quarters of 2023, compared to ¥1,726,203,979.56 in 2022[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥29,512,237,252.72, marking a 9.09% increase from ¥27,044,491,889.50 at the end of the previous year[5] - The total current liabilities increased to ¥7,071,620,719.28 from ¥6,335,606,579.88, which is an increase of approximately 11.6%[13] - Long-term borrowings rose to ¥1,394,229,071.22 from ¥1,221,797,346.84, indicating an increase of about 14.1%[13] - Total liabilities increased to ¥9,594,453,591.08 in 2023 from ¥8,590,423,576.47 in 2022, reflecting a growth of 11.7%[14] - The total assets of the company amounted to CNY 27,044,491,889.50, slightly down from CNY 27,054,123,244.38, indicating a decrease of about 0.04%[24] - Total liabilities amounted to approximately $8.59 billion, with current liabilities at about $6.34 billion and non-current liabilities at approximately $2.25 billion[25] Shareholder Equity - The equity attributable to shareholders at the end of the reporting period was ¥12,801,744,944.19, an increase of 8.39% from ¥11,807,275,548.61 at the end of the previous year[5] - Total equity attributable to shareholders reached ¥12,801,744,944.19, up from ¥11,810,494,423.01 in the previous year, marking an increase of 8.4%[14] - The company's retained earnings stood at approximately $7.26 billion, showing a slight decrease from the previous figure of $7.27 billion[25] - The total equity reached approximately $18.45 billion, with equity attributable to shareholders totaling around $11.81 billion[25] Cash Flow - The company’s cash flow from operating activities for the year-to-date period was ¥2,394,341,996.15, slightly down by 0.78% from ¥2,413,199,678.13 in the previous year[4] - Cash inflow from operating activities totaled CNY 15,053,570,654.07, an increase from CNY 12,474,599,949.97 in the previous year, representing a growth of approximately 20.5%[20] - Cash outflow from operating activities amounted to CNY 12,659,228,657.92, compared to CNY 10,061,400,271.84 in the same period last year, indicating a rise of about 25.9%[20] - Net cash flow from operating activities was CNY 2,394,341,996.15, slightly down from CNY 2,413,199,678.13, reflecting a decrease of approximately 0.8%[20] - Cash inflow from investing activities was CNY 182,867,448.79, significantly higher than CNY 82,444,226.06 in the previous year, marking an increase of about 121.5%[20] - Cash inflow from financing activities totaled CNY 283,435,000.00, a decrease from CNY 1,687,398,511.60 in the previous year, representing a decline of approximately 83.2%[21] - Net cash flow from financing activities was negative at CNY -1,173,842,441.79, compared to CNY -1,081,895,459.34 in the same period last year, indicating a worsening of about 8.5%[21] Market and Operational Insights - The company reported a 25.88% increase in operating revenue for the year-to-date period, driven by increased demand in the pharmaceutical market and enhanced marketing efforts[7] - The company continues to focus on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[10] - Research and development expenses for the first three quarters of 2023 totaled ¥150,404,351.60, an increase from ¥111,745,143.83 in 2022[18]

北京同仁堂股份有限公司 独立董事：乔延江、王桂华、王钊、杨庆英 北京同仁堂股份有限公司独立董事 根据中国证券监督管理委员会《上市公司独立董事管理办法》《上海证券交 易所股票上市规则》以及《北京同仁堂股份有限公司章程》等有关规定，作为北 京同仁堂股份有限公司（以下简称公司）的独立董事，我们对公司拟提交第九届 董事会第二十三次会议审议的《关于控股股东对公司及控股子公司委托贷款暨关 联交易的议案》，发表如下事前审核意见： 公司本次关联交易条款内容遵循了一贯的公平、合理原则，不存在损害公司 及全体股东，特别是中小股东利益的情况，并有助于满足公司生产经营需要。同 意将本议案提交公司董事会审议。 关于控股股东对公司及控股子公司委托贷款暨关联交易的 事前审核意见 2023 年 10 月 27 日 ...

证券代码：600085 证券简称：同仁堂 公告编号：2023-031 北京同仁堂股份有限公司 第九届董事会第二十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 会议召开情况 北京同仁堂股份有限公司（以下简称公司）第九届董事会第二十三次会议于 2023 年 10 月 27 日以现场结合通讯会议方式召开。本次会议通知已提前送达全 体董事，与会各位董事均已知悉与本次会议所议事项的相关必要信息。本次董事 会会议应出席董事 11 人，实际出席 11 人。公司全体监事及部分高级管理人员列 席了本次会议。会议由董事长邸淑兵先生主持，会议的召开和表决程序符合《中 华人民共和国公司法》及《北京同仁堂股份有限公司章程》（以下简称《公司章 程》）的有关规定。 二、 会议审议情况 （一） 审议通过了《2023 年第三季度报告》 董事会认为，公司 2023 年第三季度报告的编制和审议程序符合法律、法规 等规定的要求，报告的内容真实、准确、完整地反映了公司 2023 年第三季度经 营的实际情况，不存在虚假记载、误导性陈述或重大遗漏 ...

北京同仁堂股份有限公司独立董事 关于控股股东对公司及控股子公司委托贷款暨关联交易的 独立意见 根据中国证券监督管理委员会《上市公司独立董事管理办法》《上海证券交 易所股票上市规则》以及《北京同仁堂股份有限公司章程》等有关规定，作为北 京同仁堂股份有限公司（以下简称公司）的独立董事，我们对公司第九届董事会 第二十三次会议审议的《关于控股股东对公司及控股子公司委托贷款暨关联交易 的议案》，发表如下独立意见： 公司《关于控股股东对公司及控股子公司委托贷款暨关联交易的议案》，相 关交易条款内容遵循了公平、合理的原则，本次关联交易符合相关法律、法规及 《北京同仁堂股份有限公司章程》的规定，不存在损害公司及全体股东，特别是 中小股东利益的情况。全体独立董事同意本次议案。 北京同仁堂股份有限公司 独立董事：乔延江、王桂华、王钊、杨庆英 2023 年 10 月 27 日 ...

北京同仁堂股份有限公司董事会审计委员会 关于控股股东对公司及控股子公司委托贷款暨关联交易的 书面审核意见 根据《上海证券交易所股票上市规则》等相关法律、法规及《北京同仁堂股 份有限公司章程》的规定，北京同仁堂股份有限公司（以下简称公司）董事会审 计委员会全面、认真的审查了公司《关于控股股东对公司及控股子公司委托贷款 暨关联交易的议案》。董事会审计委员会认为： 本次关联交易符合公司的发展要求，有利于公司合理调配与使用资金，有效 推进实施相关项目，提高公司药品质量控制管理水平和在相关领域的业务能力。 相关交易条款内容遵循了公平、合理的原则，符合相关法律、法规及《北京同仁 堂股份有限公司章程》的规定，不存在损害公司及全体股东，特别是中小股东利 益的情况。董事会审计委员会同意将本次议案提交董事会审议。 北京同仁堂股份有限公司董事会 审计委员会：杨庆英、乔延江、温凯婷 2023 年 10 月 27 日 ...

证券代码：600085 证券简称：同仁堂 公告编号：2023-032 北京同仁堂股份有限公司 第九届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、会议召开情况 北京同仁堂股份有限公司（以下简称公司）第九届监事会第十六次会议于 2023 年 10 月 27 日以现场结合通讯会议方式召开。本次会议通知已提前送达全 体监事，与会各位监事均已知悉与本次会议所议事项的相关必要信息。本次会议 应出席监事 5 人，实际出席 5 人。会议由监事会主席李军先生主持。会议的召开 和表决程序符合《中华人民共和国公司法》《北京同仁堂股份有限公司章程》（以 下简称《公司章程》）的有关规定。 监事会认为，公司 2023 年第三季度报告的编制和审议程序符合法律、法规 等规定的要求，报告的内容真实、准确、完整地反映了公司 2023 年第三季度经 营的实际情况，不存在虚假记载、误导性陈述或重大遗漏。 表决结果：同意 5 票，反对 0 票，弃权 0 票。 (二) 审议通过了《关于控股股东对公司及控股子公司委托贷款暨关联交 易的议 ...

证券代码：600085 证券简称：同仁堂 公告编号：2023-034 北京同仁堂股份有限公司 关于控股股东对公司及控股子公司委托贷款 暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、确定性和完整性承担法律责任。 重要内容提示： 控股股东中国北京同仁堂（集团）有限责任公司（以下简称同仁堂集团） 对北京同仁堂股份有限公司（以下简称公司）及控股子公司北京同仁堂科技发展 股份有限公司（以下简称同仁堂科技）、北京同仁堂商业投资集团有限公司（以 下简称同仁堂商业）以委托贷款形式拨付国有资本经营预算资金共计人民币 8,560 万元即将期满，公司及控股子公司将与同仁堂集团继续签订委托贷款协议， 同仁堂集团将以委托贷款形式拨付国有资本经营预算资金共计 8,560 万元给公司 及控股子公司，拨付资金将投入合同约定项目。 本次交易构成关联交易，但不构成《上市公司重大资产重组管理办法》 规定的重大资产重组。本次交易事项经公司第九届董事会第二十三次会议及第九 届监事会第十六次会议审议通过，无需提交公司股东大会审议。 至本次关联交易为止，过去 12 个月内，同仁堂集 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached CNY 9,760,696,245.05, representing a 30.02% increase compared to the same period last year[13]. - The net profit attributable to shareholders was CNY 986,526,289.49, marking a 32.69% increase year-on-year[13]. - The net cash flow from operating activities was CNY 2,366,775,898.08, which is a 25.67% increase compared to the previous year[13]. - The total assets of the company at the end of the reporting period were CNY 29,058,986,690.05, reflecting a 7.41% increase from the end of the previous year[13]. - The net assets attributable to shareholders increased to CNY 12,412,636,216.71, a 5.10% rise compared to the previous year[13]. - Basic earnings per share for the first half of 2023 were CNY 0.719, up 32.66% from the same period last year[14]. - The weighted average return on net assets increased by 1.26 percentage points to 8.00%[14]. - The company reported a 33.22% increase in net profit after deducting non-recurring gains and losses, amounting to CNY 979,030,353.48[13]. - The company reported a total comprehensive income of CNY 1,657,262,716.38 for the first half of 2023, up from CNY 1,209,769,438.80 in the previous year, indicating a growth of 37.0%[104]. - The total profit for the first half of 2023 was CNY 1,864,010,649.65, compared to CNY 1,353,195,469.84 in the same period last year, reflecting a growth of 37.5%[105]. Operational Efficiency - The company is actively expanding its production capabilities through intelligent manufacturing, aiming to enhance efficiency and reduce energy consumption[21]. - The company has established multiple production bases across regions, ensuring a robust industrial cluster for its operations[21]. - The company is focused on high-quality development strategies, including the "High-Quality Development Strategy," "Fine Products Strategy," and "Large Varieties Strategy" to enhance governance and operational efficiency[23]. - The company has implemented a zero-defect quality management system and conducted comprehensive quality management enhancement activities, aiming to improve detection capabilities and establish a specialized inspection mechanism for key varieties[24]. - The company is enhancing its digital capabilities by implementing various digital management systems, including IoT digital production lines and a smart service robot to improve operational efficiency[26]. Market Position and Strategy - The company is positioned to capitalize on the growing demand for traditional Chinese medicine due to changing health perceptions and an aging population[20]. - The company is focusing on expanding its market presence and enhancing its product offerings, as indicated by the increase in R&D spending[102]. - The company plans to expand its market presence and invest in new product development to enhance growth prospects in the upcoming quarters[91]. - The company is focusing on strategic investments and potential mergers and acquisitions to strengthen its market position[91]. Environmental Compliance - The company reported a total wastewater discharge of 15.99 thousand tons, with no exceedance of discharge standards[56]. - The subsidiary Tongrentang Technology reported a total wastewater discharge of 19.77 thousand tons, also with no exceedance of discharge standards[57]. - The company has established wastewater treatment facilities at all branches, which are operating normally and in compliance with regulations[58]. - Air pollution control facilities at all branches are functioning properly, ensuring compliance with emission standards[60]. - The company has implemented noise control measures at all branches, which are operating normally and meet the required standards[60]. - The company completed the 2022 carbon emission report and third-party verification on time, with plans for carbon quota compliance in the second half of 2023[68]. Governance and Shareholder Relations - The company held its first extraordinary general meeting on January 9, 2023, where the election of Ms. Yang Qingying as an independent director was approved[49]. - The annual general meeting on June 26, 2023, reviewed 23 proposals, including the 2022 financial settlement report and the profit distribution plan, all of which were approved[50]. - Ms. Yang Qingying was elected as an independent director and chair of the audit committee of the ninth board of directors[52]. - The company has established a corporate governance structure including a shareholders' meeting, board of directors, and supervisory board[125]. Financial Position - The total assets at the end of the current period amount to approximately 19,377.43 million, showing a strong asset base[117]. - The total liabilities at the end of the current period are approximately 6,964.80 million, indicating a manageable debt level[117]. - The total owner's equity at the end of the reporting period is CNY 17,224,761,877.36, with a capital reserve of CNY 1,353,754,682.55 and retained earnings of CNY 6,623,842,916.87[119]. - The company reported a net loss attributable to owners of CNY 438,870,483.84 for the first half of 2023, compared to a loss of CNY 397,726,375.98 in the same period last year[120]. Research and Development - R&D expenses grew by 41.26% to ¥101,573,460.06, reflecting increased investment in research and development[29]. - The company is actively exploring a quality control center operation model to enhance research management capabilities and ensure public medication safety through adverse reaction monitoring[25]. Risk Management - The company has not disclosed any significant risks that could materially affect its operations during the reporting period[3]. - The company adheres to strict quality control and compliance systems, enhancing its operational management and risk management frameworks[21].

证券代码：600085 证券简称：同仁堂 公告编号：2023-030 北京同仁堂股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、 说明会召开的时间、地点 召开时间：2023 年 9 月 5 日（星期二） 上午 9:30-10:30 召开地点：上海证券报·中国证券网（http://roadshow.cnstock.com/） 召开方式：网络文字互动 1 会议召开时间：2023 年 9 月 5 日（星期二） 上午 9:30-10:30 会议召开地点：上海证券报·中国证券网（http://roadshow.cnstock.com/） 会议召开方式：网络文字互动 三、 参加人员 重要内容提示： 投资者可以在 2023 年 9 月 4 日下午 16:00 前将需要了解的情况和关注问题预 先发送到北京同仁堂股份有限公司（以下简称公司）邮箱，公司将在说明会上就 投资者普遍关注的问题进行回答。 公司于 2023 年 8 月 30 日披露了《2023 年半年度报告》，为便于广大投资 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥5,143,069,726.63, representing a 30.08% increase compared to ¥3,953,698,821.02 in the same period last year[4] - Net profit attributable to shareholders for Q1 2023 was ¥523,355,606.08, reflecting a 30.85% increase from ¥399,961,569.63 in the previous year[4] - The basic earnings per share for Q1 2023 was ¥0.382, an increase of 30.82% compared to ¥0.292 in the previous year[5] - Operating profit for Q1 2023 was ¥995,843,502.23, up 44.7% from ¥687,941,569.74 in Q1 2022[18] - The total comprehensive income for the first quarter of 2023 was CNY 772,106,058.66, an increase from CNY 548,283,148.97 in the same period of 2022, representing a growth of approximately 40.8%[19] Cash Flow and Assets - The net cash flow from operating activities reached ¥1,145,427,938.13, up 22.62% from ¥934,100,363.26 in the same period last year[5] - The company's cash and cash equivalents as of March 31, 2023, amount to approximately RMB 12.57 billion, an increase from RMB 11.62 billion at the end of 2022, reflecting a growth of about 8.15%[14] - Total current assets increased to approximately RMB 21.47 billion from RMB 20.56 billion, marking a growth of about 4.43% year-over-year[14] - The net increase in cash and cash equivalents for Q1 2023 was CNY 946,802,643.32, compared to CNY 780,999,899.77 in Q1 2022, showing an increase of approximately 21.2%[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 67,051, with the largest shareholder, Beijing Tongrentang (Group) Co., Ltd., holding 719,308,540 shares, representing 52.45% of total shares[10] - The company has no pledged, marked, or frozen shares among its top shareholders, indicating a stable ownership structure[10] - The largest institutional investor, China Industrial Bank Co., Ltd., holds 53,320,470 shares, representing 3.89% of total shares[10] - The company has not reported any significant changes in its shareholder relationships or actions among major shareholders[11] Liabilities and Equity - Total liabilities rose to ¥8,689,204,417.95 in Q1 2023, compared to ¥8,590,423,576.47 in Q1 2022, marking an increase of 1.2%[16] - Shareholders' equity attributable to the parent company was ¥12,308,524,557.01, up 4.22% from ¥11,807,275,548.61 at the end of the previous year[5] - The company's total equity reached ¥19,225,133,163.58 in Q1 2023, an increase from ¥18,463,699,667.91 in Q1 2022, reflecting a growth of 4.1%[16] Operational Insights - The company reported a 30.08% increase in operating revenue due to increased demand in the pharmaceutical market and significant sales growth from subsidiaries[9] - The accounts receivable increased by 25.10% due to the management of customer credit limits, with the overall balance being reasonable and controllable[9] - Research and development expenses for Q1 2023 were ¥45,194,023.47, a 39.1% increase from ¥32,473,405.94 in Q1 2022[18] - Selling expenses in Q1 2023 amounted to ¥934,153,949.48, up 19.2% from ¥784,042,047.02 in Q1 2022[18] Inventory and Non-Current Assets - Inventory decreased to approximately RMB 6.40 billion from RMB 6.69 billion, a decline of about 4.31%[14] - The company reported a total non-current asset value of approximately RMB 6.05 billion as of March 31, 2023, compared to RMB 6.07 billion at the end of 2022, showing a slight decrease of about 0.33%[14] Future Outlook - Future outlook includes continued investment in R&D and market expansion strategies to sustain growth momentum[17] - The report does not indicate any new product launches or technological developments during the quarter[12]